New blood test may detect fatty liver before It's too late
NCT ID NCT06225193
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at whether a blood test called the Enhanced Liver Fibrosis (ELF) test can find early signs of fatty liver disease in people who are at high risk, such as those with diabetes, high blood pressure, or heart disease. Researchers will review medical records of 300 adults to see how well the ELF test works compared to other methods like ultrasound or liver biopsy. The goal is to find a simpler way to catch liver problems early.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a simpler, non-invasive blood test to catch fatty liver disease early in people at high risk.
- What could go wrong
- This is an early, retrospective study, not a treatment trial. The ELF test may not prove better than existing methods, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with 18 years of age, NAFLD/NASH and non-NAFLD/NASH who have assessed with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: ≥ 18 years * NAFLD/NASH and non-NAFLD/NASH patients who have had an assessment with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023. Exclusion Criteria: * Patients with incomplete data and those lost to follow up.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fatty liver are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Methodist Dallas Medical Center
RECRUITINGDallas, Texas, 75203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brown Fat's hidden role in fatty liver disease under investigation
- A blood test could map how the liver heals after alcohol damage
- Can a single pill tackle both fatty liver and diabetes?
- A simple scan and blood test could catch silent liver scarring before It's too late
- A simple body scan may spot fatty liver disease without needles
- Could a common b vitamin tame fatty liver?